The approvals open the door for substantial equity-linked financing. Monitor for definitive ELOC and preferred stock purchase agreements with C/M Capital over the next 90 days, as the terms (pricing, maximum share count, conversion/redemption mechanics) will determine actual dilution. The stock's tiny market cap makes any new issuance highly dilutive in percentage terms.
Price Chart
Executive Summary
Jaguar Health's 2026 Annual Meeting concluded on June 8, 2026 after two adjournments, with stockholders approving all five proposals including director election, auditor ratification, and two equity issuance authorizations to C/M Capital Master Fund LP. The approvals permit the issuance of more than 19.99% of outstanding common stock under an ELOC agreement and a preferred stock purchase agreement, both to be finalized within 90 days, representing significant potential future dilution. No financial results or guidance were provided in this routine governance filing.
Key Facts
- All five stockholder proposals were approved at the June 8, 2026 reconvened annual meeting.
- Proposal 3 approved issuance of >19.99% of outstanding common stock to C/M Capital Master Fund via an ELOC agreement, with 3,891,273 For, 291,441 Against.
- Proposal 4 approved issuance of >19.99% of outstanding common stock to C/M Capital via a Preferred Stock Purchase Agreement (Series P Non-Convertible Preferred), with 3,846,847 For, 336,712 Against.
- 14,044,277 shares were outstanding and entitled to vote as of the April 15, 2026 record date; 7,169,152 shares (51%) were represented at the meeting.
- John Micek III was elected Class II director with 3,967,085 For and 240,944 Withheld.
- RBSM LLP was ratified as independent auditor for FY2026 with 6,898,326 For, 238,443 Against.
Financial Impact
Shareholder approval allows the company to issue more than 19.99% of outstanding common stock under an ELOC and a preferred stock purchase agreement with C/M Capital within 90 days. The number of shares and pricing are undisclosed, but the potential dilution is material relative to the current ~$2M market cap.
Risk Factors
- Potential severe dilution from issuance of >19.99% of outstanding shares under ELOC and preferred stock agreements.
- No pricing terms disclosed yet — adverse terms could further pressure the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-261910 |
| Document: d85703dex991.htm | 0001193125-26-261910 |
| Document: 0001193125-26-261910-index-headers.html | 0001193125-26-261910 |
| Document: 0001193125-26-261910-index.html | 0001193125-26-261910 |
| Document: 0001193125-26-261910.txt | 0001193125-26-261910 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | S-3 | $2.04 | awaiting T+60 | — | $2.04 (+0.00%) |
Oct 8, 2026 18d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.04 (+57.41%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.04 (+56.87%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.04 (+66.11%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.04 (+73.51%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.04 (+71.10%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.04 (+71.10%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.04 (−94.08%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.04 (−808.28%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.04 (+80.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers